Amikacin (hydrate)

Amikacin hydrate (BAY 41-6551 hydrate) is an aminoglycoside antibiotic and a semisynthetic analog of kanamycin. Amikacin hydrate is bactericidal, acting directly on the 30S and 50S bacerial ribosomal subunits to inhibit protein synthesis. Amikacin hydrate is very active against most Gram-negative bacteria including gentamicin- and tobramycin-resistant strains. Amikacin hydrate also inhibits the infections caused by susceptible Nocardia and nontuberculous mycobacteria[1][2].

Product Specifications

CAS Number

[1257517-67-1]

Product Name Alternative

BAY 41-6551 (hydrate)

UNSPSC

12352211

Target

Antibiotic; Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection; Cancer

Assay Protocol

https://www.medchemexpress.com/amikacin-hydrate.html

Purity

99.93

Solubility

DMSO : < 1 mg/mL|H2O : 50 mg/mL (ultrasonic)

Smiles

O[C@@H]1[C@H]([C@@H](C[C@H](N)[C@H]1O[C@@]([C@@H]([C@@H](O)[C@@H]2O)O)([H])O[C@@H]2CN)NC([C@@H](O)CCN)=O)O[C@@]([C@@H]([C@@H](N)[C@@H]3O)O)([H])O[C@@H]3CO.[x].O

Molecular Formula

C22H43N5O13.xH2O

References & Citations

[1]Edson, R.S. and C.L. Terrell, The aminoglycosides. Mayo Clin Proc, 1999. 74 (5) : p. 519-28.|[2]Ristuccia AM, et al. An overview of amikacin. Ther Drug Monit. 1985;7 (1) :12-25.|[3]Siân R Kitcher, et al. ORC-13661 Protects Sensory Hair Cells From Aminoglycoside and Cisplatin Ototoxicity. JCI Insight. 2019 Aug 8;4 (15) :e126764.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

Aminoglycoside

Citation 01

Antibiotics (Basel) . 2021 Sep 14;10 (9) :1110.|Appl Microbiol Biotechnol. 2022 Apr;106 (7) :2689-2702.|Curr Microbiol. 2021 Dec 14;79 (1) :12.|J Antimicrob Chemother. 2020 Jul 1;75 (7) :1850-1858.|ACS Chem Biol. 2022 Jan 21;17 (1) :39-53.|bioRxiv. 2024 May 10.|Int J Antimicrob Agents. 2018 Aug;52 (2) :269-271.|Nat Commun. 2022 Mar 2;13 (1) :1116.|ACS Infect Dis. 2024 Apr 12;10 (4) :1327-1338.|AMB Express. 2024 Dec 24;14 (1) :141.|Antimicrob Agents Chemother. 2024 Oct 29:e0094524.|Antimicrob Agents Chemother. 2025 May 23:e0024925.|Authorea. 2025 Sep 17.|bioRxiv. 2025 May 30.|Commun Biol. 2025 Oct 6;8 (1) :1425.|EBioMedicine. 2025 May 30:117:105776.|Eur J Clin Microbiol Infect Dis. 2025 Jun;44 (6) :1493-1500.|Eur J Clin Microbiol Infect Dis. 2025 Sep 29.|Int J Antimicrob Agents. 2025 Jun 9:107551.|Int J Med Microbiol. 2023 Mar 28;313 (2) :151578.|J Antimicrob Chemother. 2020 Sep 1;75 (9) :2609-2615.|J Clin Microbiol. 2025 Aug 20:e0084125.|Microbiol Spectr. 2025 May 19:e0307424.|Pathogens. 2025 Mar 21;14 (4) :302.